SAN FRANCISCO, July 02, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022 – May 10, 2023 Lead Plaintiff Deadline: Aug. 29, 2023 Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-916-0895 ImmunityBio, Inc.…Read More
Related Posts
ProMedica committed to Coldwater until a sale is completed
COLDWATER -- The sale of ProMedica Coldwater Regional Hospital is pending approval by Michigan's attorney general.
Electric Curtains Market Industry 2023 Competitive Insights and Precise Outlook HunterDouglas Somfy Budget Blinds
New Jersey, (United States) - The research carried out in this large scale Electric Curtains Market report succours clients to forecast investment in an emerging market, expansion of market share…
Ultragenyx Pharmaceutical Inc Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
NOVATO, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases,…
